WASHINGTON - The biotech and pharmaceutical makers' support for getting a follow-on biologics bill passed this year is an attempt to "cut a deal" with Congress to secure at least 12 years of data exclusivity, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association (GPhA). (BioWorld Today) Read More
